BeOne Medicines Showcases Expanding Oncology Pipeline With More Than 60 Presentations at ASCO and EHA 2026
BeOne Medicines Ltd. has announced a major presence at two of the world’s leading oncology conferences in 2026, highlighting the company’s rapidly expanding influence in both hematologic malignancies and solid tumors. More than 60 abstracts from BeOne’s oncology portfolio have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and the 2026 European Hematology Association (EHA) Congress in Stockholm.
The presentations will feature data across a broad range of blood cancers and solid tumors, underscoring the company’s ambition to strengthen its leadership position in cancer research and drug development. The accepted studies include long-term follow-up data, next-generation targeted therapies, combination regimens, and several promising pipeline candidates that are advancing toward pivotal clinical trials.
A major focus of the company’s presentations will be chronic lymphocytic leukemia (CLL), where BeOne plans to showcase both its established therapies and emerging investigational medicines. The company stated that the upcoming data reinforce its strategy of improving patient outcomes through durable treatment responses while continuing to innovate for future generations of therapies.
Among the most anticipated updates are new long-term findings from the SEQUOIA clinical trial evaluating BRUKINSA® (zanubrutinib), the company’s BTK inhibitor for CLL. The study includes 78 months of follow-up data, providing one of the longest evaluations of a BTK inhibitor in frontline CLL treatment.
According to BeOne, the updated SEQUOIA findings continue to demonstrate durable disease control and long-term efficacy in patients receiving BRUKINSA. The data are expected to further strengthen the therapy’s position as a foundational treatment option for patients with CLL. The company emphasized that the results highlight the importance of long-term treatment durability and effective sequencing strategies in managing chronic blood cancers.
The SEQUOIA trial also includes a significant subgroup analysis focused on patients aged 80 years and older. Researchers described this as one of the largest and longest-followed elderly patient populations ever studied in a phase 3 CLL trial. Preliminary findings suggest that advanced age did not reduce the benefits associated with treatment, an important consideration given that many CLL patients are older adults who often face additional health challenges.
BeOne executives believe the data demonstrate the company’s commitment to improving treatment outcomes across diverse patient populations. The company has positioned BRUKINSA as a key component of its hematology franchise while simultaneously investing heavily in next-generation therapies designed to address treatment resistance and improve long-term survival.
One of the company’s most closely watched investigational programs is BGB-16673, a BTK degrader currently being evaluated in relapsed or refractory CLL. Updated findings on the therapy will be presented during an oral session at EHA 2026.
The investigational drug has shown promising clinical activity along with a manageable safety profile in heavily pretreated patients. BeOne also plans to present new data involving BTK-naïve patients, marking the first time such findings will be shared publicly.
BGB-16673 has become one of the most advanced BTK degraders currently in clinical development, with more than 1,100 patients dosed across studies. Researchers are hopeful that BTK degraders may offer a new therapeutic approach for patients who develop resistance to existing BTK inhibitors.
In addition to its BTK-focused programs, BeOne is advancing sonrotoclax, a next-generation BCL2 inhibitor being studied in combination with zanubrutinib. New data from the all-oral combination therapy will be presented at both ASCO and EHA.
The company reported that the combination demonstrated deep treatment responses, rapid achievement of undetectable minimal residual disease (MRD), durable remissions, and a generally well-tolerated safety profile. Researchers believe the regimen may represent a future time-limited treatment strategy capable of delivering long-lasting benefits without requiring indefinite therapy.
Amit Agarwal, M.D., Ph.D., Chief Medical Officer for Hematology at BeOne Medicines, said the upcoming presentations highlight the company’s long-term commitment to leadership in CLL research and treatment innovation.
He noted that achieving durable long-term efficacy remains essential in CLL management and emphasized that BeOne is continuing to advance new therapies designed to improve outcomes across multiple lines of treatment. According to Agarwal, the company’s expanding pipeline reflects its strategy of both strengthening current standards of care and shaping the future of hematologic oncology.
Beyond hematology, BeOne is also showcasing significant progress across its solid tumor portfolio at ASCO 2026. The company will feature seven distinct investigational and approved therapies in multiple oral presentations and poster sessions spanning breast, gynecologic, lung, liver, and gastrointestinal cancers.
One of the major highlights includes first clinical data from BGB-43395, a highly selective CDK4 inhibitor being studied in hormone receptor-positive, HER2-negative breast cancer. Early phase 1 findings are expected to provide insights into the drug’s safety profile and anti-tumor activity in first-line treatment settings.
The company will also present data on BG-C9074, a B7-H4-targeting antibody-drug conjugate (ADC). Early-stage clinical findings from the dose-escalation and safety expansion portions of the phase 1 study will be shared in a rapid oral presentation.
Another investigational therapy drawing attention is BGB-B2033, a novel GPC3 x 4-1BB bispecific antibody being studied in hepatocellular carcinoma. Initial clinical results from heavily pretreated liver cancer patients are expected to highlight the therapy’s potential as a first-in-class immuno-oncology approach.
BeOne is also continuing to expand the clinical reach of its PD-1 inhibitor TEVIMBRA® (tislelizumab). At ASCO, the company plans to present subgroup analyses from the HERIZON-GEA-01 trial, which evaluated TEVIMBRA in combination with ZIIHERA® (zanidatamab) and chemotherapy in HER2-positive gastroesophageal adenocarcinoma.
The study demonstrated statistically significant improvements in both overall survival and progression-free survival regardless of PD-L1 expression levels. The collaboration with Jazz Pharmaceuticals reflects BeOne’s broader strategy of combining immunotherapy with targeted therapies to improve treatment outcomes in difficult-to-treat cancers.
Mark Lanasa, M.D., Ph.D., Chief Medical Officer for Solid Tumors at BeOne Medicines, said the ASCO presentations reflect the company’s rapidly growing scientific capabilities and pipeline strength.
According to Lanasa, BeOne is accelerating the development of innovative therapies across several high-need cancer types while moving multiple programs toward late-stage clinical trials. He stated that the company aims to build long-term leadership positions in breast, lung, gynecologic, and gastrointestinal cancers where significant unmet medical needs remain.
The company’s growing global oncology footprint will also be highlighted during an investor webcast scheduled for June 1, 2026. The webcast will be led by BeOne co-founder, chairman, and CEO John V. Oyler along with members of the company’s leadership team and invited oncology experts.
During the event, company executives are expected to review key clinical updates presented at ASCO, discuss strategic priorities, and provide insights into BeOne’s research and development platforms. The webcast will also focus on the company’s long-term growth strategy and its efforts to accelerate innovation across oncology.
The large number of accepted abstracts at ASCO and EHA demonstrates the increasing momentum behind BeOne Medicines as it continues expanding its global oncology portfolio. With significant progress across both blood cancers and solid tumors, the company is positioning itself as a major force in next-generation cancer therapeutics.
As competition intensifies in oncology drug development, BeOne’s strategy of combining established therapies with innovative pipeline programs may help the company strengthen its presence in some of the most important and rapidly evolving areas of cancer treatment.
About BRUKINSA® (zanubrutinib)
BRUKINSA is an orally available, small molecule inhibitor of Bruton’s tyrosine kinase (BTK) designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.
With the broadest label globally, BRUKINSA is the foundational BTK inhibitor. It is also the only BTK inhibitor to provide the flexibility of once or twice daily dosing and the only BTK inhibitor to demonstrate superiority to another BTK inhibitor in a Phase 3 study.
The global BRUKINSA clinical development program includes more than 8,000 patients enrolled in over 30 countries and regions across more than 45 trials. BRUKINSA is approved in 80 markets in at least one indication, and more than 290,000 patients have been treated globally.
About BEQALZI™ (sonrotoclax)
BEQALZI™ (sonrotoclax) is a foundational, next-generation and potentially best-in-class B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Preclinical and clinical studies in early drug development have shown that sonrotoclax is a highly potent and specific BCL2 inhibitor with a short half-life and no drug accumulation. BEQALZI has shown promising clinical activity across a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL), and is in development as a monotherapy and in combination with other therapeutics, including zanubrutinib. To date, more than 2,200 patients have been enrolled across the broad sonrotoclax global development program.
About BGB-16673
BGB-16673 is a foundational and potential first-in-class and best-in-class Bruton’s tyrosine kinase (BTK) degrader for the treatment of B-cell malignancies. With 1,100+ patients dosed to date in an extensive global clinical development program, BGB-16673 is the most advanced BTK degrader in the clinic. This program includes three randomized Phase 3 trials in R/R CLL, including the head-to-head Phase 3 trial versus pirtobrutinib, which began enrolling in Q4 2025. Originating from BeOne’s chimeric degradation activation compound (CDAC) platform, BGB-16673 is designed to promote the degradation, or breakdown, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease.
The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL). Additionally, the European Medicines Agency (EMA) granted BGB-16673 PRIority MEdicines (PRIME) designation for the treatment of patients with Waldenstrom’s macroglobulinemia (WM) previously treated with a BTK inhibitor.
About ZIIHERA (zanidatamab)
ZIIHERA (zanidatamab) is a bispecific human epidermal growth factor receptor 2, or HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.1
Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is approved in China for the treatment of patients who have unresectable, locally advanced, or metastatic HER2-high expression (IHC 3+) biliary tract cancer (BTC) and who have received prior systemic therapy. ZIIHERA has also been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for eligible BTC patients.
Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule. BeOne has licensed zanidatamab from Zymeworks in Asia (excluding India and Japan), Australia and New Zealand. Jazz Pharmaceuticals has rights in all other regions.
ZIIHERA is a registered trademark of Zymeworks BC Inc.
About TEVIMBRA (tislelizumab)
TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.
TEVIMBRA is the foundational asset of BeOne’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 15,000 patients enrolled to date in 30+ countries and regions across 71 trials, including 21 registration-enabling studies. TEVIMBRA is approved in over 50 countries, and more than 2 million patients have been treated globally.
